Beren Therapeutics raises $300M in a combined equity and debt financing round led by CEO Jason Camm, targeting commercial readiness for its lead asset.
Amount Raised
$300 Million
Round Type
Debt Financing
Thousand OaksBiotechnologyHealth CareTherapeuticsDescription
Beren Therapeutics, based in Thousand Oaks, California, raised $300M in a combined equity and debt financing round. The funds will support commercial readiness activities for its lead asset and expand diagnostic integration networks. The company has advanced its product for FDA Breakthrough Therapy Designation and is in the Priority Review track. The financing will also aid in building a long-term patient access and family support program.
Quick answer
Beren Therapeutics raised $300 Million in a Debt Financing round, dated June 10, 2026. Beren Therapeutics is based in Thousand Oaks, California, United States.
- How much did Beren Therapeutics raise?
- Beren Therapeutics raised $300 Million in a Debt Financing round on June 10, 2026.
- What does Beren Therapeutics do?
- Beren Therapeutics is a developer of cyclodextrin-based cholesterol trafficking therapeutics, focused on addressing infantile-onset Niemann-Pick disease, type C. The company is advancing its lead asset, adrabetadex,..
- Where is Beren Therapeutics based and how big is it?
- Beren Therapeutics is based in Thousand Oaks, California, United States.
- Who are the decision-makers at Beren Therapeutics?
- Fundz holds 2 contacts at Beren Therapeutics, including the Director, Talent Acquisition. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Beren Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Definium Therapeutics raised $805M (Post-IPO Equity) on July 24, 2026.
- Scancell Holdings PLC raised $39M (Post-IPO Equity) on July 23, 2026.
- Mentari Therapeutics raised $200M (Post-IPO Equity) on July 22, 2026.
- Tikva Allocell Pte. Ltd raised $8M (Series A) on July 22, 2026.
- Transcripta Bio raised $24M (Series A) on July 22, 2026.
- Immitra Bio raised $2.5M (Pre-Seed) on July 21, 2026.
Who to call at Beren Therapeutics, and when
A new round usually means Beren Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Beren Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Beren Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Beren Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Beren Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Beren Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.